Subscribe to RSS
DOI: 10.1055/s-0041-1733927
Arterial Thrombosis in Cancer Patients: An Update
![](https://www.thieme-connect.de/media/sth/202108/lookinside/thumbnails/10-1055-s-0041-1733927_02923-1.jpg)
Abstract
Cancer is associated with an increased incidence of both venous thromboembolism (VTE) and arterial thrombosis (cardiovascular events and ischemic stroke). Cancer-associated arterial thrombotic events are less well studied than VTE, but increasingly recognized, particularly in specific malignancies and in association with specific anticancer therapies. The pathogenesis of arterial thrombotic events in cancer is complex and involves generation of tumor-associated procoagulant factors and a variety of alterations in platelet function as well as in the coagulation and fibrinolytic systems, and endothelial injury and dysfunction, that combine to produce hypercoagulability. The multifactorial interaction between this prothrombotic state, the individual cardiovascular risk, advanced age and presence of comorbidities, and the specific neoplasm characteristics and therapy, may induce the vascular events. Recent studies based on population databases and prospective or retrospective analyses with prolonged follow-up highlight that cancer patients experience an increased (approximately 1.5–2-fold) risk of both cerebrovascular and cardiovascular events compared with noncancer individuals, which peaks in the time period of the diagnosis of cancer but may persist for years. Beyond the type of cancer, the risk reflects the tumor burden, being higher in advanced stages and metastatic cancers. The occurrence of arterial thromboembolic events is also associated with increased overall mortality. We here present an update of the pathophysiology, risk factors, clinical evidence, and treatment considerations on cancer-associated arterial thrombosis, in the light of the need for specific multidisciplinary prevention and surveillance strategies in this setting, in the frame of cardio-oncology approaches.
Publication History
Article published online:
31 August 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Trousseau A. Phlegmasia alba dolens. In: Trousseau A. ed. Clinique médicinale de l'Hotel-Dieu de Paris. France: JB Bailliere et fils; 1865: 645-712
- 2 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (06) 809-815
- 3 Heit JA, O'Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162 (11) 1245-1248
- 4 Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005; 128 (03) 291-302
- 5 Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24 (01) 29-38
- 6 Prandoni P, Lensing AW, Büller HR. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327 (16) 1128-1133
- 7 Franchini M, Montagnana M, Favaloro EJ, Lippi G. The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost 2009; 35 (07) 644-653
- 8 Franchini M, Mannucci PM. Thrombin and cancer: from molecular basis to therapeutic implications. Semin Thromb Hemost 2012; 38 (01) 95-101
- 9 Franchini M, Bonfanti C, Lippi G. Cancer-associated thrombosis: investigating the role of new oral anticoagulants. Thromb Res 2015; 135 (05) 777-781
- 10 Franchini M, Mannucci PM. Low-molecular-weight heparins and cancer: focus on antitumoral effect. Ann Med 2015; 47 (02) 116-121
- 11 Canale ML, Bisceglia I, Lestuzzi C, Parrini I. ANMCO Cardio-Oncology Task Force. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res 2019; 39 (09) 4619-4625
- 12 Visweshwar N, Jaglal M, Sokol L, Djulbegovic B. Hematological malignancies and arterial thromboembolism. Indian J Hematol Blood Transfus 2019; 35 (04) 611-624
- 13 Oren O, Herrmann J. Arterial events in cancer patients-the case of acute coronary thrombosis. J Thorac Dis 2018; 10 (Suppl. 35) S4367-S4385
- 14 Tufano A, Coppola A, Galderisi M. The growing impact of cardiovascular oncology: epidemiology and pathophysiology. Semin Thromb Hemost 2021; (e-pub ahead of print). DOI: 10.1055/s-0041-1729885.
- 15 Kwaan HC. The unique hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2014; 40 (03) 332-336
- 16 Kwaan HC, Weiss I, Tallman MS. The tole of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute promyelocytic leukemia. Semin Thromb Hemost 2019; 45 (06) 612-621
- 17 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
- 18 Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 2006; 32 (01) 24-32
- 19 Østerud B, Bjørklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32 (01) 11-23
- 20 Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11 (3-4): 249-266
- 21 Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32 (01) 54-70
- 22 Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract 2011; 2011: 394740
- 23 Mezouar S, Frère C, Darbousset R. et al. Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences. Thromb Res 2016; 139: 65-76
- 24 Connolly GC, Phipps RP, Francis CW. Platelets and cancer-associated thrombosis. Semin Oncol 2014; 41 (03) 302-310
- 25 van Es N, Sturk A, Middeldorp S, Nieuwland R. Effects of cancer on platelets. Semin Oncol 2014; 41 (03) 311-318
- 26 Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008; 8 (08) 1247-1255
- 27 Lee EC, Cameron SJ. Cancer and thrombotic risk: the platelet paradigm. Front Cardiovasc Med 2017; 4: 67
- 28 Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost 2019; 45 (04) 413-422
- 29 Tuzovic M, Herrmann J, Iliescu C, Marmagkiolis K, Ziaeian B, Yang EH. Arterial thrombosis in patients with cancer. Curr Treat Options Cardiovasc Med 2018; 20 (05) 40
- 30 Herrmann J, Lerman A. The endothelium: dysfunction and beyond. J Nucl Cardiol 2001; 8 (02) 197-206
- 31 Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25 (02) 173-182
- 32 Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res 2014; 133 (Suppl. 02) S149-S157
- 33 Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer 2011; 2 (12) 1085-1096
- 34 Rachidi S, Metelli A, Riesenberg B. et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol 2017; 2 (11) eaai7911
- 35 Aronson D, Brenner B. Arterial thrombosis and cancer. Thromb Res 2018; 164 (Suppl. 01) S23-S28
- 36 Lancellotti P, Trung M-LN, Oury C, Moonen M. Cancer and cardiovascular mortality risk: is the die cast?. Eur Heart J 2021; 42 (01) 110-112
- 37 Zamorano JL, Lancellotti P, Rodriguez Muñoz D. et al; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (36) 2768-2801
- 38 Zwang L, Wang F, Chen L, Geng Y, Yu S, Chen Z. Long-term cardiovascular disease mortality among 160 834 five-year survivors of adolescent and young adult cancer: an American population-based cohort study. Eur Heart J 2021; 42 (01) 101-109
- 39 Chen P-C, Muo C-H, Lee Y-T, Yu Y-H, Sung F-C. Lung cancer and incidence of stroke: a population-based cohort study. Stroke 2011; 42 (11) 3034-3039
- 40 Zöller B, Ji J, Sundquist J, Sundquist K. Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 2012; 48 (12) 1875-1883
- 41 Zöller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 2012; 48 (01) 121-128
- 42 Navi BB, Reiner AS, Kamel H. et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70 (08) 926-938
- 43 Reiner AS, Navi BB, DeAngelis LM, Panageas KS. Increased risk of arterial thromboembolism in older men with breast cancer. Breast Cancer Res Treat 2017; 166 (03) 903-910
- 44 Grilz E, Königsbrügge O, Posch F. et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica 2018; 103 (09) 1549-1556
- 45 Navi BB, Howard G, Howard VJ. et al. New diagnosis of cancer and the risk of subsequent cerebrovascular events. Neurology 2018; 90 (23) e2025-e2033
- 46 Navi BB, Howard G, Howard VJ. et al. The risk of arterial thromboembolic events after cancer diagnosis. Res Pract Thromb Haemost 2019; 3 (04) 639-651
- 47 Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013; 11 (02) 223-233
- 48 Navi BB, Reiner AS, Kamel H. et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019; 133 (08) 781-789
- 49 Yu J, Li A, Laureano M, Crowther M. Frequency of arterial thromboembolism in populations with malignancies: a systematic review. Thromb Res 2019; 184: 16-23
- 50 Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 2014; 40 (03) 348-358
- 51 Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 571-581
- 52 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122 (13) 2176-2184
- 53 Barbui T, Finazzi G, Carobbio A. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
- 54 Carobbio A, Thiele J, Passamonti F. et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (22) 5857-5859
- 55 Campbell PJ, Scott LM, Buck G. et al; United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366 (9501): 1945-1953
- 56 Carobbio A, Finazzi G, Antonioli E. et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112 (08) 3135-3137
- 57 Barbui T, Vannucchi AM, Carobbio A. et al. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol 2017; 92 (01) E5-E6
- 58 Hultcrantz M, Björkholm M, Dickman PW. et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms. Ann Intern Med 2018; 168 (05) 317-325
- 59 De Stefano V, Ghirardi A, Masciulli A. et al. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood 2020; 135 (05) 381-386
- 60 Arcasoy MO. Arterial thrombosis and second cancer in MPNs. Blood 2020; 135 (05) 301-302
- 61 Elting LS, Rubenstein EB, Martin CG. et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001; 19 (04) 1137-1146
- 62 Hakim DA, Dangas GD, Caixeta A. et al. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Am Heart J 2011; 161 (02) 391-396
- 63 Iliescu CA, Grines CL, Herrmann J. et al. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and sociedad Latino Americana de Cardiologıa intervencionista). Catheter Cardiovasc Interv 2016; 87 (05) E202-E223
- 64 Santoro C, Capone V, Canonico ME. et al. Single, dual and triple antithrombotic therapy in cancer patients with coronary artery disease: searching for evidence and personalized approaches. Semin Thromb Hemost 2021; (e-pub ahead of print). DOI: 10.1055/s-0041-1726298.
- 65 Cardwell CR, Kunzmann AT, Cantwell MM. et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology 2014; 146 (03) 700-708.e2
- 66 Ye XF, Wang J, Shi WTHJ, He J. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. Br J Cancer 2014; 111 (11) 2172-2179